ES2196874T3 - Composicion que contiene ubiquinona adecuada para promover el transporte intramitocondrial de ubiquinosas y procedimientos de uso de dicho composicion. - Google Patents

Composicion que contiene ubiquinona adecuada para promover el transporte intramitocondrial de ubiquinosas y procedimientos de uso de dicho composicion.

Info

Publication number
ES2196874T3
ES2196874T3 ES99954343T ES99954343T ES2196874T3 ES 2196874 T3 ES2196874 T3 ES 2196874T3 ES 99954343 T ES99954343 T ES 99954343T ES 99954343 T ES99954343 T ES 99954343T ES 2196874 T3 ES2196874 T3 ES 2196874T3
Authority
ES
Spain
Prior art keywords
composition
ubiquinosas
intramitocondrial
ubiquinone
transportation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99954343T
Other languages
English (en)
Inventor
Janos Feher
Grazia Sears
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau HealthScience SpA
Original Assignee
Sigma Tau HealthScience SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11343466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2196874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau HealthScience SpA filed Critical Sigma Tau HealthScience SpA
Application granted granted Critical
Publication of ES2196874T3 publication Critical patent/ES2196874T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)

Abstract

Uso de: (a) una benzoquinona liposoluble seleccionada del grupo formado por coenzima Q10 (CoQ10), su forma reducida, ubiquinol-10 (CoQ10H2) ó mezcla de ambos, en cantidad efectiva para desarrollar una actividad terapéutica y/o preventiva y/o nutricional en personas con déficit de la misma, en combinación con (b) al menos un ácido graso poliinsaturado omega-3 o un éster del mismo, para preparar una composición farmacéutica/nutricional para la prevención o tratamiento de mitocondriopatías.
ES99954343T 1998-10-21 1999-10-19 Composicion que contiene ubiquinona adecuada para promover el transporte intramitocondrial de ubiquinosas y procedimientos de uso de dicho composicion. Expired - Lifetime ES2196874T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998BO000596A IT1304406B1 (it) 1998-10-21 1998-10-21 Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.

Publications (1)

Publication Number Publication Date
ES2196874T3 true ES2196874T3 (es) 2003-12-16

Family

ID=11343466

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99954343T Expired - Lifetime ES2196874T3 (es) 1998-10-21 1999-10-19 Composicion que contiene ubiquinona adecuada para promover el transporte intramitocondrial de ubiquinosas y procedimientos de uso de dicho composicion.

Country Status (11)

Country Link
US (1) US6417233B1 (es)
EP (1) EP1123093B1 (es)
AR (1) AR023338A1 (es)
AT (1) ATE237323T1 (es)
AU (1) AU1074600A (es)
DE (1) DE69907010T2 (es)
DK (1) DK1123093T3 (es)
ES (1) ES2196874T3 (es)
IT (1) IT1304406B1 (es)
PT (1) PT1123093E (es)
WO (1) WO2000023069A1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1307281B1 (it) 1999-11-25 2001-10-30 Simonelli Giuseppe Uso di ubichinone q10 per il trattamento locale e la prevenzione dipatalogie oftalmologiche secondarie alla terapia fotorefrattiva,
EA006429B1 (ru) * 2001-03-09 2005-12-29 Сосьете Де Продюи Нестле С.А. Композиция для предупреждения или восстановления возрастных функциональных дефицитов у млекопитающих и способ ее применения
ES2210056T3 (es) * 2001-04-12 2004-07-01 Vesifact Ag Preconcentrados en microemulsion y microemulsiones que contienen coenzima q10.
US6582723B2 (en) * 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP4603192B2 (ja) * 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
ATE291910T1 (de) * 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
ITRM20010755A1 (it) * 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
TW200302056A (en) * 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
KR20110112481A (ko) * 2002-11-04 2011-10-12 오션 뉴트리션 캐나다 리미티드 다중 쉘을 갖는 마이크로캡슐 및 이의 제조 방법
US20040208939A1 (en) * 2003-04-18 2004-10-21 Barry Sears Novel dietary compositions to reduce inflammation
US7875291B1 (en) 2003-09-05 2011-01-25 Glu-Pro, Inc. Composition for managing diabetes, obesity, and hyperlipidemia and associated methods
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
TW200524579A (en) * 2003-11-28 2005-08-01 Kaneka Corp Composition for protecting liver functions
EP1701716A1 (en) * 2004-01-08 2006-09-20 Kaneka Corporation Antiaging composition
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US7390507B2 (en) * 2004-04-13 2008-06-24 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
DE102004041270A1 (de) * 2004-08-26 2006-03-02 Merz Pharma Gmbh & Co. Kgaa Ein Kapillar- Wirksystem enthaltende Zusammensetzungen mit anwendungsbezogener Differenzierbarkeit und deren Verwendung
US8034450B2 (en) * 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
WO2006109194A2 (en) * 2005-01-27 2006-10-19 Ocean Nutrition Canada Ltd. Chromium-fatty acid compounds and methods of making and using thereof
EP1846355B1 (en) 2005-01-27 2009-12-16 Ocean Nutrition Canada Limited Fatty acid-benzenediol derivatives and methods of making and using thereof
ES2619303T3 (es) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
US9968120B2 (en) * 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
SI1933821T1 (sl) * 2005-09-15 2020-11-30 Ptc Therapeutics, Inc. Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev
CN101547687A (zh) * 2005-11-17 2009-09-30 生物药效率有限公司 生物相容的潜在乳化剂
NZ569068A (en) 2005-12-20 2011-11-25 Cenestra Llc Omega 3 fatty acid formulations of EPA and DHA
US20070184041A1 (en) * 2006-02-09 2007-08-09 Burja Adam M Methods and compositions related to production of coenzyme q10
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
WO2007120500A2 (en) * 2006-04-07 2007-10-25 Ocean Nutrition Canada Ltd. Emulsions and microcapsules with substances having low interfacial tension, methods of making and using thereof
US8491888B2 (en) * 2006-05-05 2013-07-23 Softgel Formulators, Inc. Highly absorbable coenzyme Q10 composition and method of producing same
MX306461B (es) * 2006-06-05 2013-01-07 Ocean Nutrition Canada Ltd Microcapsulas con cubiertas mejoradas
KR100801057B1 (ko) * 2006-07-18 2008-02-04 삼성전자주식회사 컬러 보정 블럭을 구비하는 ｃｍｏｓ 이미지 센서 및 그이미지 센싱 방법
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
EP2098229A4 (en) * 2006-12-28 2010-03-10 Suntory Holdings Ltd NERVE REGENERATION MEDIUM
EP2124905B1 (en) 2007-01-10 2016-09-07 DSM Nutritional Products AG Microcapsules including pea protein
US20110027348A1 (en) 2007-08-27 2011-02-03 Janos Feher Composition and method inhibiting inflammation
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
KR100943652B1 (ko) * 2007-12-28 2010-02-25 (주)미토콘 생체이용율이 향상된 코엔자임큐10 함유 조성물
MX2010011032A (es) 2008-04-11 2011-03-01 Cytotech Labs Llc Star Metodos y uso de induccion de apoptosis en celulas cancerigenas.
US8535660B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US8535659B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010111397A1 (en) * 2009-03-24 2010-09-30 Adds Pharmaceuticals Llc Stabilized solubility-enhanced formulations for oral delivery
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
US10052299B2 (en) 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
SG10202010355PA (en) * 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
JP6145087B2 (ja) 2011-04-26 2017-06-07 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ酸化関与障害
JP6106157B2 (ja) 2011-04-26 2017-03-29 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． 神経変性障害および筋疾患に関与するｐｕｆａ
WO2012148930A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
KR102112087B1 (ko) 2011-04-26 2020-05-18 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
WO2012174286A1 (en) * 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
EP2720680B1 (en) 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
CA2916513A1 (en) * 2013-07-03 2015-01-08 Barrie Tan Coq10 (ubiquinone, ubiquinol), vitamin a (retinoic acid, retinol), vitamin e (tocotrienol, tocopherol) and methods of use
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
EP3950649A1 (en) 2015-11-23 2022-02-09 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
DE202015106479U1 (de) 2015-11-29 2016-03-09 Cathleen Straßburger Stapelhilfe und Abdeckhaube für den Transport von Cateringmaterial zum Kunden
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
IL295783B2 (en) 2020-02-21 2026-03-01 Retrotope Inc Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
DE3224619A1 (de) 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Orale pharmazeutische zusammensetzung
JP2643217B2 (ja) 1988-01-22 1997-08-20 エーザイ株式会社 脂溶性物質水性液
US5895652A (en) 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
NO304009B1 (no) 1997-02-04 1998-10-12 Gunnar Volden Hudpreparat
CA2260397A1 (en) * 1999-01-29 2000-07-29 Atlantis Marine Inc. Method of converting rendered triglyceride oil from marine sources into bland, stable food oil

Also Published As

Publication number Publication date
DE69907010D1 (de) 2003-05-22
US6417233B1 (en) 2002-07-09
WO2000023069A1 (en) 2000-04-27
EP1123093A1 (en) 2001-08-16
ITBO980596A1 (it) 2000-04-21
AR023338A1 (es) 2002-09-04
DK1123093T3 (da) 2003-08-11
IT1304406B1 (it) 2001-03-19
DE69907010T2 (de) 2004-02-19
AU1074600A (en) 2000-05-08
ATE237323T1 (de) 2003-05-15
EP1123093B1 (en) 2003-04-16
PT1123093E (pt) 2003-09-30
ITBO980596A0 (it) 1998-10-21

Similar Documents

Publication Publication Date Title
ES2196874T3 (es) Composicion que contiene ubiquinona adecuada para promover el transporte intramitocondrial de ubiquinosas y procedimientos de uso de dicho composicion.
BR9810866A (pt) Composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos
ES2169197T3 (es) Composicion farmaceutica que comprende una alcanoil l-carnitina en combinacion con un acido graso poliinsaturado de la serie omega-3 para la prevencion y el tratamiento de trastornos del metabolismo de los lipidos.
AU3955089A (en) Pharmaceutical composition comprising protein kinase c inhibitor and anti-cancer agent
DE60120659D1 (de) Zusammensetzungen enthaltend carotenoide und deren verwendung zur verhinderung hormon-induzierter nebenwirkungen
ATE431133T1 (de) Präparat zur verhinderung und/oder behandlung von demenz syndromen
ES2174928T3 (es) Metodo para incrementar la diodisponibilidad de composiciones farmaceuticas orales.
BR0113564A (pt) Composição para produto pessoal, composição bifásica e sistema de limpeza
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
BR9811058A (pt) Formulação auto-emulsificante para compostos lipofìlicos
AR015946A1 (es) Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis
IT1274734B (it) Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
ATE301454T1 (de) Feste lipidzusammensetzungen von lipophilen verbindungen zur verbesserten oralen bioverfügbarkeit
CO5170479A1 (es) Emulsion aceite en agua que comprende un agente biologicamente activo micronizado y un sistema emulsionante adecuado saturado y un mono de ester de acido acrilico. .
DE69836335D1 (de) Natürliche inhaltsstoffe enthaltende nahrungsergänzungsstoffe
AR035001A1 (es) Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento
DK1121115T3 (da) PUFA-tilskud
BRPI0009373B8 (pt) composições farmacêuticas orais contendo triglicerídeos de cadeia longa e tensoativos lipofílicos
WO2002043659A3 (en) Composition containing statins and calcium for improved cardiovascular health
ES2014060A6 (es) Procedimiento para la obtencion de productos farmaceuticos que actuan en particualr sobre el corazon y el sistema cardiovascular.
AR019592A1 (es) Productos liquidos con contenido de eritritol
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
EP0856315A4 (en) MEDICINAL COMPOSITION
CA2124605A1 (en) Prevention and improvement of medical symptoms caused by leucotriene b4
DE60135927D1 (en) Nd